Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced new data demonstrating that its next-generation Percepta(R) Genomic Sequencing Classifier (GSC)...
Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....
Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced that it has named Sangeeta Bhorade, M.D., medical director of pulmonology. In this role, Dr. Bhorade...
Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced that Bonnie H. Anderson, chairman and chief executive officer, is scheduled to present at the...
Veracyte, Inc. (Nasdaq: VCYT) announced today the closing of its public offering of 6,325,000 shares of common stock, including 825,000 shares sold upon full exercise of the underwriters'...
SmarTrend identified an Uptrend for Veracyte Inc (NASDAQ:VCYT) on January 4th, 2019 at $14.02. In approximately 4 months, Veracyte Inc has returned 71.61% as of today's recent price of $24.06.
Veracyte, Inc. (Nasdaq: VCYT) (the "Company") today announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a public offering price of $23.25 per...
Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....
Veracyte, Inc. (Nasdaq: VCYT) ("the Company") today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock. All of the shares are being offered...
SOUTH SAN FRANCISCO, Calif. (AP) _ Veracyte Inc. (VCYT) on Tuesday reported a loss of $1.9 million in its first quarter.
NEW YORK, NY / ACCESSWIRE / April 30, 2019 / Veracyte, Inc. (NASDAQ: ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on April 30, 2019 at 5:00 PM Eastern Time....
SmarTrend identified an Uptrend for Veracyte Inc (NASDAQ:VCYT) on January 4th, 2019 at $14.02. In approximately 4 months, Veracyte Inc has returned 64.55% as of today's recent price of $23.07.
Veracyte (VCYT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced today that it has received regulatory authorization from the New York State Department of Health to...
Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced that it has named Alfred "Freddie" Bowie, Jr., Ph.D., as vice president, corporate and business...
Veracyte, Inc. announced today that a new study published online in BMC Systems Biology showcases the development of the Afirma(R) Genomic Sequencing Classifier (GSC) and its ability...
Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...
Veracyte, Inc. (Nasdaq: VCYT) today announced that it will release its financial results for the first quarter 2019 after the close of market on Tuesday, April 30, 2019. Company management...
SmarTrend identified an Uptrend for Veracyte Inc (NASDAQ:VCYT) on January 4th, 2019 at $14.02. In approximately 3 months, Veracyte Inc has returned 73.04% as of today's recent price of $24.26.
Veracyte, Inc. announced that data published online today in The Lancet Respiratory Medicine suggest that use of the company's Envisia Genomic Classifier improves diagnosis for patients...
